Cambridge-based Beam Therapeutics Inc. is making waves in the biotechnology industry by developing precision genetic medicines to aid patients fighting serious diseases in the United States. Among its impressive portfolio are BEAM-101 and BEAM-102, which target sickle cell disease beta thalassemia, as well as BEAM-201, an allogenic chimeric antigen receptor T cell that aims to tackle refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma. In addition, the company is developing liver-targeting LNP formulations in the form of BEAM-301 and BEAM-302, which have shown impressive promise in treating glycogen storage disease 1a and severe alpha-1 antitrypsin deficiency, respectively. Beam Therapeutics Inc. isn't going it alone, either. The company has various research collaboration agreements, including a partnership with Pfizer Inc. that centers around in vivo base editing programs that target rare genetic diseases affecting the liver, muscle, and central nervous system. Apellis Pharmaceuticals and Beam Therapeutics are conducting preclinical research on clearly defining body-specific genes within the complement system in the liver, brain, and the eye. Meanwhile, Verve Therapeutics is teaming up with the company to research cardiovascular disease treatments. Beam Therapeutics has also partnered with Sana Biotechnology, Orbital Therapeutics, and The Institute of Molecular and Clinical Ophthalmology Basel on a range of initiatives aimed at developing new treatments for an array of conditions from impaired vision to blindness, and more. Incorporated back in 2017, the future looks bright for this exciting biotech start-up.
Beam Therapeutics's ticker is BEAM
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 201-500 employees working at Beam Therapeutics
It is beamtx.com/about-us
Beam Therapeutics is in the Healthcare sector
Beam Therapeutics is in the Biotechnology industry
The following five companies are Beam Therapeutics's industry peers: